Validation Requirements for Disinfection Efficacy - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Validation Requirements for Disinfection Efficacy

Pharmaceutical Technology
Volume 37, Issue 1, pp. 35


More in GMPs/Validation

Q Is the periodic re-evaluation of disinfectant efficacy useful in any way? I have been asked to repeat these studies even though they have been done in the past. There's been no change to the materials or methods since that time.

John S. Kent
A In the pharmaceutical manufacturing industry, operating under GMPs, the periodic revalidation of disinfection efficacy is not scientifically justified or required provided the disinfectant used remains the same, the dilution of the disinfectant is still the same, the challenge organisms (including environmental isolates) are still the same, the manufacturing environment surfaces are still the same and the vendor for the disinfectant is still the same. To my knowledge, only when one of these five elements regarding cleanroom disinfection is changed are you required to repeat the validation of disinfection efficacy testing. Periodic revalidation of a disinfectant serves no useful scientific purpose and I do not know of an FDA regulation that states that one must periodically revalidate disinfectants. Be sure to execute the disinfection efficacy validation properly and have complete documentation.

John S. Kent, PhD
Principal, Pharmaceutical Development Consulting
San Mateo, CA (USA) 94403


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here